Stoke Therapeutics Presents New Open-Label Extension (OLE) Study Data That Further Support the Potential for Zorevu ...
December 6, 2024
– Substantial and durable reductions in convulsive seizure frequency observed in patients treated with 2 or 3 doses of 70mg f ...Stoke Therapeutics Receives FDA Breakthrough Therapy Designation for Zorevunersen for the Treatment of Dravet Syndr ...
December 4, 2024
– Supported by evidence from clinical studies that indicate that zorevunersen may demonstrate substantial improvement over av ...Stoke Therapeutics Announces Plans to Present New Data that Support Zorevunersen as Potentially the First Disease-M ...
December 2, 2024
– Company to host a virtual educational event for investors and research analysts on Monday, December 9 at 8:30 am Eastern ( ...Stoke Therapeutics Reports Third Quarter Financial Results and Provides Business Updates
November 5, 2024
– Company plans to provide seizure as well as cognition and behavior data from all patients treated with initial 70mg doses f ...Stoke Therapeutics Presents Zorevunersen Data Showing Substantial Reductions in Seizures and Improvements in Multip ...
September 10, 2024
– New data showed improvements in cognition and behavior during the first year of treatment with additional increases demonst ...Stoke Therapeutics Appoints Eric Olson, MS, MBA as Chief Business Officer
September 4, 2024
– Mr. Olson brings two decades of successful corporate business development experience with an emphasis on rare diseases and ...Stoke Therapeutics to Present Encore Data at the 15th European Epilepsy Congress that Demonstrate the Potential for ...
September 3, 2024
– First presentation of landmark data from Phase 1/2a and OLE studies of zorevunersen that showed substantial reductions in s ...Stoke Therapeutics to Present at Upcoming Investor Conferences in September
September 3, 2024
BEDFORD, Mass. --(BUSINESS WIRE)--Sep. 3, 2024-- Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated t ...Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
August 16, 2024
BEDFORD, Mass. --(BUSINESS WIRE)--Aug. 16, 2024-- Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated ...Stoke Therapeutics Reports Second Quarter Financial Results and Provides Business Updates
August 7, 2024
– FDA removes Partial Clinical Hold as company advances toward a Phase 3 registrational study of zorevunersen (STK-001) in ch ...Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
July 16, 2024
BEDFORD, Mass. --(BUSINESS WIRE)--Jul. 16, 2024-- Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated ...Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
June 18, 2024
BEDFORD, Mass. --(BUSINESS WIRE)--Jun. 18, 2024-- Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated ...Stoke Therapeutics to Present at Upcoming Investor Conferences in June
June 3, 2024
BEDFORD, Mass. --(BUSINESS WIRE)--Jun. 3, 2024-- Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated t ...Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
May 17, 2024
BEDFORD, Mass. --(BUSINESS WIRE)--May 17, 2024-- Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated t ...Stoke Therapeutics Reports First Quarter Financial Results and Provides Business Updates
May 6, 2024
– Recent data demonstrating reductions in seizure frequency and improvements in cognition and behavior support the potential ...Stoke Therapeutics Appoints Thomas Leggett as Chief Financial Officer
April 29, 2024
– Mr. Leggett brings more than two decades of experience as an investment banker and corporate executive leading financial st ...Stoke Therapeutics Appoints Jason Hoitt as Chief Commercial Officer
April 17, 2024
– Mr. Hoitt brings more than two decades of successful commercial experience with an emphasis on rare diseases – BEDFORD, Mas ...Stoke Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference
April 4, 2024
BEDFORD, Mass. --(BUSINESS WIRE)--Apr. 4, 2024-- Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated t ...Stoke Therapeutics Announces Pricing of Upsized $125 Million Public Offering
March 27, 2024
BEDFORD, Mass. --(BUSINESS WIRE)--Mar. 27, 2024-- Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated ...Stoke Therapeutics Announces Proposed Public Offering
March 26, 2024
BEDFORD, Mass. --(BUSINESS WIRE)--Mar. 26, 2024-- Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated ...Stoke Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
March 25, 2024
– As of December 31, 2023 , Company had $201.4 million in cash, cash equivalents, and marketable securities, anticipated to f ...Stoke Therapeutics Announces Landmark New Data That Support the Potential for STK-001 to be the First Disease-Modif ...
March 25, 2024
– Phase 1/2a End of Study Data: 70mg doses demonstrated substantial and sustained reductions in convulsive seizure frequency ...Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
January 17, 2024
BEDFORD, Mass. --(BUSINESS WIRE)--Jan. 17, 2024-- Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated ...Stoke Therapeutics Highlights Strategic Priorities and Anticipated Milestones for 2024
January 8, 2024
– Data anticipated in Q1 2024 from studies of STK-001 for the treatment of Dravet syndrome – – End of Phase 1/2a study result ...Stoke Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 4, 2024
BEDFORD, Mass. --(BUSINESS WIRE)--Jan. 4, 2024-- Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated t ...